Lisata Therapeutics Announces Participation in InfoSec World 2023
20 Settembre 2023 - 2:00PM
Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the
“Company”), a clinical-stage pharmaceutical company developing
innovative therapies for the treatment of advanced solid tumors and
other serious diseases, announces that Gregory Berkin, Chief
Information Officer at Lisata, will participate at InfoSec World
2023 being held September 25-27, 2023, in Lake Buena Vista,
Florida.
Mr. Berkin will be a panelist in a keynote discussion, titled
“CISO Leadership: Harnessing the Power and Managing the Risks of
Artificial Intelligence (AI),” on Wednesday, September 27, 2023 at
8:15 a.m. – 9:30 a.m. Eastern Time. For more information on about
the keynote and InfoSec World 2023, please visit
https://www.infosecworldusa.com/isw23/session/1555328/.
About Lisata Therapeutics
Lisata Therapeutics is a clinical-stage pharmaceutical company
dedicated to the discovery, development and commercialization of
innovative therapies for the treatment of advanced solid tumors and
other major diseases. Lisata’s lead product candidate, LSTA1, is an
investigational drug designed to activate a novel uptake pathway
that allows co-administered or tethered anti-cancer drugs to target
and penetrate solid tumors more effectively. Based on Lisata’s
CendR Platform® Technology, Lisata has already established
noteworthy commercial and R&D partnerships. The Company expects
to announce numerous clinical study and business milestones over
the next two years and has projected that its current business and
development plan is funded with available capital through these
milestones and into early 2026. For more information on the
Company, please visit www.lisata.com.
Contact:
Investors and Media:
Lisata Therapeutics, Inc.John MendittoVice President, Investor
Relations and Corporate
CommunicationsPhone: 908-842-0084Email: jmenditto@lisata.com
Grafico Azioni Lisata Therapeutics (NASDAQ:LSTA)
Storico
Da Set 2024 a Ott 2024
Grafico Azioni Lisata Therapeutics (NASDAQ:LSTA)
Storico
Da Ott 2023 a Ott 2024